Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...

Disorders of Leukocytes

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

Disorders of Erythrocytes

Disorders of Erythrocytes

Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

In vivo CAR T cell generation to treat cancer and autoimmune disease.

Science (New York, N.Y.)·2025

Same author

HER2 and HLA-A*02 dual CAR-T cells utilize LOH in a NOT logic gate to address on-target off-tumor toxicity.

Journal for immunotherapy of cancer·2023

Same author

The Genetic Landscape of Hematopoietic Stem Cell Frequency in Mice.

Stem cell reports·2015

Same author

Prolonged fasting reduces IGF-1/PKA to promote hematopoietic-stem-cell-based regeneration and reverse immunosuppression.

Cell stem cell·2014

Same author

Adipocytic cells augment the support of primitive hematopoietic cells in vitro but have no effect in the bone marrow niche under homeostatic conditions.

Stem cells and development·2013

Same author

Placental growth factor expression is required for bone marrow endothelial cell support of primitive murine hematopoietic cells.

PloS one·2013

Search research articles

Related Experiment Video

Updated: Jun 28, 2026

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm

Published on: December 22, 2016

Myeloproliferative disorder by TKO.

Gregor B Adams¹

¹Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, University of Southern California, Keck School of Medicine, 1450 Biggy Street (NRT 4507), Los Angeles, CA 90033, USA. gregor.adams@keck.usc.edu

|October 23, 2008

Summary

Researchers deleted all three retinoblastoma tumor suppressor genes in hematopoietic stem cells. This genetic alteration caused a myeloproliferative disorder, demonstrating the genes' crucial role in blood cell development.

More Related Videos

Immunophenotyping and Cell Sorting of Human MKs from Human Primary Sources or Differentiated In Vitro from Hematopoietic Progenitors

Immunophenotyping and Cell Sorting of Human MKs from Human Primary Sources or Differentiated In Vitro from Hematopoietic Progenitors

Published on: August 7, 2021

Related Experiment Videos

Last Updated: Jun 28, 2026

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm

Published on: December 22, 2016

Immunophenotyping and Cell Sorting of Human MKs from Human Primary Sources or Differentiated In Vitro from Hematopoietic Progenitors

Immunophenotyping and Cell Sorting of Human MKs from Human Primary Sources or Differentiated In Vitro from Hematopoietic Progenitors

Published on: August 7, 2021

Area of Science:

Hematology
Cancer Biology
Stem Cell Research

Background:

The retinoblastoma tumor suppressor gene family (RB1, RBL1, RBL2) plays a critical role in cell cycle regulation.
Hematopoietic stem cells (HSCs) are essential for lifelong blood cell production and are susceptible to genetic alterations.
Understanding the function of tumor suppressor genes in HSCs is vital for comprehending stem cell disorders and developing therapeutic strategies.

Discussion:

Viatour et al. investigated the in vivo function of the entire retinoblastoma tumor suppressor gene family in HSCs.
Complete deletion of these genes led to a severe myeloproliferative disorder, characterized by uncontrolled blood cell proliferation.
The study highlights the cell-autonomous nature of the disease, indicating that the genetic alterations within primitive hematopoietic cells directly drive the pathology.

Key Insights:

The simultaneous loss of all three retinoblastoma tumor suppressor family members is oncogenic in hematopoietic stem cells.
This genetic inactivation results in a myeloproliferative neoplasm that is intrinsic to the affected hematopoietic cells.
Primitive hematopoietic cells are the cellular origin of the observed myeloproliferative disorder.

Outlook:

Further research into the specific downstream pathways affected by the loss of retinoblastoma tumor suppressors in HSCs.
Exploring potential therapeutic targets for myeloproliferative disorders arising from retinoblastoma gene family dysfunction.
Investigating the role of these tumor suppressors in other stem cell populations and their implications for various cancers.